<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968106</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2021-01</org_study_id>
    <secondary_id>2021-001085-37</secondary_id>
    <nct_id>NCT04968106</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Retroperitoneal Sarcomas (TORNADO)</brief_title>
  <acronym>TORNADO</acronym>
  <official_title>Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Retroperitoneal Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Biosciences International Sàrl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to&#xD;
      assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant&#xD;
      chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (1:1)&#xD;
      phase II trial. Patients will be randomized between arm A (neodjuvant chemotherapy by&#xD;
      doxorubicin + ifosfamide) and arm B (neodjuvant chemotherapy by doxorubicin + ifosfamide and&#xD;
      retifanlimab) with one patient randomized in arm A for one patient randomized in arm B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (1:1) phase II trial. Patients will be randomized between arm A (neodjuvant chemotherapy by doxorubicin + ifosfamide) and arm B (neodjuvant chemotherapy by doxorubicin + ifosfamide and retifanlimab) with one patient randomized in arm A for one patient randomized in arm B</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the antitumor activity of retifanlimab when prescribed in association with neoadjuvant chemotherapy (doxorubicin+ifosfamide)</measure>
    <time_frame>5 months after treatment onset</time_frame>
    <description>Antitumor activity will be assessed in terms of histological response based on surgical sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall Survival (OS) is defined as the time from study treatment initiation to death (of any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall Survival (OS) is defined as the time from study treatment initiation to death (of any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile independently for each arm: Common Terminology Criteria for Adverse event version 5</measure>
    <time_frame>Throughout the treatment period, an expected average of 6 months</time_frame>
    <description>Toxicity will be grade using the Common Terminology Criteria for adverse events version 5 and coded according to the standardized medical terminology MedDRA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Retroperitoneal Sarcoma</condition>
  <condition>Resectable Sarcoma</condition>
  <arm_group>
    <arm_group_label>Standard Arm A: treatment by neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment by doxorubicin and ifosfamide followed by surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment by doxorubicin, ifosfamide and retifanlimab followed by surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 4 cycles</description>
    <arm_group_label>Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab</arm_group_label>
    <arm_group_label>Standard Arm A: treatment by neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 4 cycles</description>
    <arm_group_label>Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab</arm_group_label>
    <arm_group_label>Standard Arm A: treatment by neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCMGA00012</intervention_name>
    <description>Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 4 cycles</description>
    <arm_group_label>Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab</arm_group_label>
    <other_name>Retifanlimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with retroperitoneal sarcoma histologically confirmed,&#xD;
&#xD;
          2. For TLS status determination: available archived FFPE tumor tissue sample.&#xD;
&#xD;
          3. Presence of mature tertiary lymphoid structures. Except if presence of TLS have been&#xD;
             already confirmed by Biopathological platform at Bergonié Institute, presence of TLS&#xD;
             should be confirmed by central review based on FFPE tumor tissue sample (archived or&#xD;
             newly obtained by biopsy for research purpose).&#xD;
&#xD;
          4. Non-metastatic and resectable disease,&#xD;
&#xD;
          5. At least one lesion that can be biopsied for research purpose,&#xD;
&#xD;
          6. No prior treatment for the disease under study,&#xD;
&#xD;
          7. Age ≥ 18 years,&#xD;
&#xD;
          8. ECOG ≤ 1,&#xD;
&#xD;
          9. Life expectancy &gt; 3 months,&#xD;
&#xD;
         10. Patients must have measurable disease defined as per RECIST v1.1&#xD;
&#xD;
         11. Adequate hematological, renal, metabolic and hepatic function&#xD;
&#xD;
         12. Left ventricular ejection fraction ≥ 50% assessed by ECHO or MUGA within 6 months from&#xD;
             study entry,&#xD;
&#xD;
         13. Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to study entry. .&#xD;
&#xD;
         14. Both women and men must agree to use a highly effective method of contraception&#xD;
             throughout the treatment period and for one year after discontinuation of treatment&#xD;
             for women and 4 months for men.&#xD;
&#xD;
         15. No prior or concurrent malignant disease diagnosed or treated in the last 2 years&#xD;
             except for adequately treated in situ carcinoma of the cervix, concomitant endometrial&#xD;
             carcinoma stage IA grade 1, basal or squamous skin cell carcinoma, or in situ&#xD;
             transitional bladder cell carcinoma,&#xD;
&#xD;
         16. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment&#xD;
             (excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2)&#xD;
             according to the National Cancer Institute Common Terminology Criteria for Adverse&#xD;
             Events (NCI-CTCAE, version 5),&#xD;
&#xD;
         17. Voluntarily signed and dated written informed consent prior to any study specific&#xD;
             procedure,&#xD;
&#xD;
         18. Patients with a social security in compliance with the French law.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment for retroperitoneal sarcoma including surgery, chemotherapy or&#xD;
             radiotherapy&#xD;
&#xD;
          2. Previous treatments with doxorubicin, daunorubicin, epirubicin, idarubicin and/or&#xD;
             other anthracyclines or anthracenediones at the maximum cumulative dose,&#xD;
&#xD;
          3. Known hypersensitivity to any involved study drug or any of its formulation&#xD;
             components,&#xD;
&#xD;
          4. Has an active or ongoing infection requiring systemic therapy,&#xD;
&#xD;
          5. Known central nervous system malignancy (CNS),&#xD;
&#xD;
          6. Women who are pregnant or breast feeding,&#xD;
&#xD;
          7. Has known active hepatitis B or hepatitis C,&#xD;
&#xD;
          8. Has a known history of Human Immunodeficiency Virus (HIV),&#xD;
&#xD;
          9. Previous enrolment in the present study,&#xD;
&#xD;
         10. Patient unable to follow and comply with the study procedures because of any&#xD;
             geographical, social or psychological reasons,&#xD;
&#xD;
         11. Has received a live attenuated vaccine or a live vaccine within 30 days prior to the&#xD;
             first dose of trial treatment, Note: the killed virus vaccines used for seasonal&#xD;
             influenza vaccines for injection are allowed; however intranasal influenza vaccines&#xD;
             (e.g., FluMist®) are live attenuated vaccines and are not allowed.&#xD;
&#xD;
         12. Uncontrolled or significant cardiovascular disease including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               1. Myocardial infarction or stroke/transient ischemic attack within the 6 months&#xD;
                  prior to study entry.&#xD;
&#xD;
               2. Uncontrolled angina within the 3 months prior to study entry.&#xD;
&#xD;
               3. Any history of clinically significant arrhythmias (such as ventricular&#xD;
                  tachycardia, ventricular fibrillation, or torsades de pointes, or poorly&#xD;
                  controlled atrial fibrillation).&#xD;
&#xD;
               4. Corrected QT (QTc) prolongation &gt; 480 msec.&#xD;
&#xD;
               5. History of other clinically significant cardiovascular disease (i.e.,&#xD;
                  cardiomyopathy, congestive heart failure with New York Heart Association [NYHA]&#xD;
                  functional classification III-IV, pericarditis, significant pericardial effusion,&#xD;
                  significant coronary stent occlusion, poorly controlled venous thrombus).&#xD;
&#xD;
         13. Uncontrolled or significant renal disease including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               1. Acute or uncontrolled urinary infection at study entry,&#xD;
&#xD;
               2. Hemorrhagic cystitis at study entry,&#xD;
&#xD;
               3. Presence of blood on dipstick at study entry,&#xD;
&#xD;
               4. Vesical atony,&#xD;
&#xD;
               5. Known urinary tract obstruction.&#xD;
&#xD;
         14. Patients with known history of active inflammatory bowel diseases, including those&#xD;
             with small or large intestine inflammation, such as Crohn's disease or ulcerative&#xD;
             colitis, will be excluded from the study,&#xD;
&#xD;
         15. Has received systemic antibiotics within 14 days before the first dose of study&#xD;
             treatment. Participants receiving prophylactic antibiotics (e.g., for prevention of a&#xD;
             urinary tract infection or chronic obstructive pulmonary disease) are eligible.&#xD;
&#xD;
         16. History of organ transplant, including allogeneic stem cell transplantation.&#xD;
&#xD;
         17. Receiving probiotics as of the first dose of study treatment.&#xD;
&#xD;
         18. Has an active autoimmune disease&#xD;
&#xD;
               -  Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease&#xD;
                  not requiring immunosuppressive treatment are eligible,&#xD;
&#xD;
               -  Patients requiring hormone replacement with corticosteroids are eligible if the&#xD;
                  steroids are administered only for the purpose of hormonal replacement and at&#xD;
                  dose ≤ 10 mg or 10 mg equivalent prednisone day,&#xD;
&#xD;
               -  Administration of steroids through a route known to result in a minimal systemic&#xD;
                  exposure (topical, intranasal, intra-ocular, intra-articular or inhalation) are&#xD;
                  acceptable.&#xD;
&#xD;
         19. Evidence of interstitial lung disease, history of interstitial lung disease, or&#xD;
             active, noninfectious pneumonitis.&#xD;
&#xD;
         20. Palliative radiation therapy administered within 1 week of first dose of study&#xD;
             treatment or radiation therapy in the thoracic region that is &gt; 30 Gy within 6 months&#xD;
             of the first dose of study treatment. Note: Participants must have recovered from all&#xD;
             radiation-related toxicities (to Grade &gt;1 or baseline), not require corticosteroids&#xD;
             for this purpose, and not have had radiation pneumonitis.&#xD;
&#xD;
         21. Person under judicial protection or deprived of liberty.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine ITALIANO, MD, PhD</last_name>
    <phone>+33556333333</phone>
    <email>a.italiano@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone MATHOULIN-PELISSIER, MD, PhD</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine ITALIANO, MD, PhD</last_name>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mehdi BRAHMI, MD</last_name>
      <email>mehdi.brahmi@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah WATSON, MD</last_name>
      <email>sarah.watson@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier MIR, MD</last_name>
      <email>olivier.mir@gutaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retroperitoneal sarcoma</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>mature tertiary lymphoid structures</keyword>
  <keyword>immune checkpoint inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

